Prostate-specific antitumor activity by probasin promoter-directed p202 expression

Molecular Carcinogenesis

Volumn 37, Issue 3, 2003, Pages 130-137

  Wen, Yong ^a   Giri, Dipak ^a   Yan, Duen Hwa ^a   Spohn, Bill ^a   Zinner, Ralph G ^a   Xia, Weiya ^a   Thompson, Timothy C ^b   Matusik, Robert J ^c   Hung, Mien Chie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclin B; p202; P55cdc; Probasin; Tumorigenecity

Indexed keywords

ANDROGEN RECEPTOR; CYCLIN B; LIPOSOME; PROBASIN; PROTEIN; PROTEIN P202; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DNA MICROARRAY; DNA VECTOR; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG SPECIFICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; NONVIRAL GENE THERAPY; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; XENOGRAFT;

ANDROGEN-BINDING PROTEIN; ANIMALS; CARRIER PROTEINS; CELL CYCLE PROTEINS; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN B; DOWN-REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE THERAPY; HUMANS; IMMUNOENZYME TECHNIQUES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPOSOMES; MALE; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NUCLEAR PROTEINS; PHENOTYPE; PHOSPHOPROTEINS; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RETINOBLASTOMA PROTEIN; SURVIVAL RATE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

VECTORS;

EID: 0041630907     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.10129     Document Type: Article

References (38)

1. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Ann Rev Biochem 1987;56:727-777.
2. Lengyel P. Tumor-suppressor genes: News about the interferon connection. Proc Natl Acad Sci USA 1993;90:5893-5895.
3. Shou J, Soriano R, Hayward SW, et al. Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. Proc Natl Acad Sci USA 2002;99:2830-2835.
4. Sokawa Y, Watanabe Y, Kawade Y. Interferon suppresses the transition of quiescent 3T3 cells to a growing state. Nature 1977;268:236-238.
5. Balkwill F, Taylor-Papadimitriou J. Interferon affects both G1 and S + G2 in cells stimulated from quiescence to growth. Nature 1978;274:798-800.
6. Einat M, Resnitzky D, Kimchi A. Close link between reduction of c-myc expression by interferon and G0/G1 arrest. Nature 1985;313:597-600.
7. Sen GC, Lengyel P. The interferon system-a bird's eye view of its biochemistry. J Biol Chem 1992;267:5017-5020.
8. Hobeika AC, Subramaniam PS, Johnson HM. IFN-a induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells. Oncogene 1997;14:1165-1170.
9. Sica G, Fabbroni L, Castagnetta L, Cacciatore M, Pavone-Macaluso M. Antiproliferative effects of interferons on human prostate carcinoma cell lines. Urol Res 1989;17:111-115.
10. van Moorselaar RJ, van Stratum P, Borm G, Debruyne FM, Schalken JA. Differential antiproliferative activities of alpha and gamma-interferon and tumor necrosis factor alone or in combinations against two prostate cancer xenografts transplanted in nude mice. Prostate 1991;18:331-344.
11. Sokoloff MH, Tso C-L, Kaboo R, et al. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Cancer 1996;77:1862-1872.
12. Ahre A, Bjorkholm M, Osterberg A, Brenning G, Gahrton G, Gyllenhammar H. High doses of natural alpha interferon in the treatment of multiple myeloma-a pilot study from the myeoloma group of central Sweden. Eur J Hematol 1988;41:123-130.
13. Kirkwood J, Harris J, Vera R, Sandler S, Fischer D, Khanderkar J. A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: The American Cancer Society collaborative trial. Cancer Res 1985;45:863-871.
14. Choubey D, Snoddy J, Chaturvedi V, et al. Interferons as gene activators-indications for repeated gene duplication during the evolution of a cluster of interferon-activatable genes on murine chromosome 1. J Biol Chem 1989;264:17182-17189.
15. Lengyel P, Choubey D, Li S-J, Datta B. The interferon-activatable gene 200 cluster: From structure toward function. Sem Virol 1995;6:203-213.
16. Choubey D. P202: An interferon-inducible negative regulator of cell growth. J Biol Regul Homeost Agents 2000;14:187-192.
17. Lembo D, Angeretti A, Benefazio S, et al. Constitutive expression of the interferon-inducible protein p202 in NIH3T3 cells affects cell cycle progression. J Biol Regul Homeost Agents 1995;9:42-46.
18. Choubey D, Li S-J, Datta B, Gutterman JU, Lengyel P. Inhibition of E2F-mediated transcription by p202. EMBO J 1996;15:5668-5678.
19. Wen Y, Yan DH, Spohn B, et al. Tumor suppression and sensitization to tumor necrosis factor alpha-induced apoptosis by an interferon-inducible protein, p202, in breast cancer cells. Cancer Res 2000;60:42-46.
20. Wen Y, Yan DH, Wang B, et al. p202, an interferon-inducible protein, mediates multiple anti-tumor activities in human pancreatic cancer xenograft models. Cancer Res 2001;61:7142-7147.
21. Yan DH, Wen Y, Spohn B, Choubey D, Gutterman JU, Hung MC. Reduced growth rate and transformation phenotype of the prostate cancer cells by an interferon-inducible protein, p202. Oncogene 1999;18:807-811.
22. Zhang J, Thomas TZ, Kasper S, Matusik RJ. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 2000;141:4698-4710.
23. Xie X, Zhao X, Liu Y, et al. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer. Cancer Res 2001;61:6795-6804.
24. Andriani F, Nan B, Yu J, et al. Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells. J Natl Cancer Inst 2001;93:1314-1324.
25. Nurse P. Universal control mechanism regulating onset of M-phase. Nature 1990;344:503-508.
26. Hardwick KG. The spindle checkpoint. Trends Genet 1998;14:1-4.
27. Gorbsky GJ. Cell cycle checkpoints: Arresting progress in mitosis. Bioessays 1997;19:193-197.
28. Xia W, Lau YK, Zhang HZ, et al. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res 1997;3:3-9.
29. Zou Y, Peng H, Zhou B, et al. Systemic tumor suppression by the proapoptotic gene bik. Cancer Res 2002;62:8-12.
30. Pettaway CA, Pathak S, Greene G, et al. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 1996;2:1627-1636.
31. Stephenson RA, Dinney CP, Gohji K, et al. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst 1992;84:951-957.
32. Choubey D, Lengyel P. Interferon action: Cytoplasmic and nuclear localization of the interferon-inducuble 52-kDa protein that is encoded by the Ifi202 gene from the gene 200 cluster. J Interferon Res 1993;13:43-52.
33. Johnstone RW, Trapani JA. Transcription and growth regulatory functions of the HIN-200 family of proteins. Mol Cell Biol 1999;19:5833-5838.
34. Jenster G. Ligand-independent activation of the androgen receptor in prostate cancer by growth factors and cytokines. J Pathol 2000;191:227-228.
35. Scher HI, Zhang ZF, Nanus D, Kelly WK. Hormone and antihormone withdrawal: Implications for the management of androgen-independent prostate cancer. Urology 1996;47:61-69.
36. Kumar R, Atlas I. Interferon a induces the expression of retinoblastoma gene product in human Burkitt lymphoma Daudi Cells: Role in growth regulation. Proc Natl Acad Sci USA 1992;89:6599-6603.
37. Zhang K, Kumar R. Interferon-a inhibits cycline E and cycline D1-dependent CDK-2 kinase activity associated with RB protein and E2F in Daudi cells. Biochem Biophys Res Commun 1994;200:522-528.
38. Resnitzky D, Tiefenbrun N, Berissi H, Kimchi A. Interferons and interleukin 6 suppress phosphorylation of the retinoblastoma protein in growth-sensitive hematopoietic cells. Proc Natl Acad Sci USA 1992;89:402-406.